Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) PT at $48.57

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $55.1429.

A number of analysts have recently weighed in on OMCL shares. Zacks Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. UBS Group set a $53.00 price objective on shares of Omnicell in a research report on Friday, January 16th. Wells Fargo & Company upped their target price on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a report on Wednesday, January 7th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a report on Thursday, January 22nd.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently modified their holdings of the business. WINTON GROUP Ltd acquired a new stake in shares of Omnicell in the 2nd quarter valued at approximately $2,692,000. State of Alaska Department of Revenue increased its stake in Omnicell by 8.7% in the second quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company’s stock valued at $819,000 after purchasing an additional 2,242 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Omnicell by 1.3% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after purchasing an additional 17,680 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in Omnicell in the second quarter worth $2,476,000. Finally, Assenagon Asset Management S.A. boosted its position in shares of Omnicell by 1,316.2% during the third quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock worth $4,284,000 after purchasing an additional 130,742 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Up 1.4%

NASDAQ OMCL opened at $46.69 on Monday. The stock’s 50 day simple moving average is $46.16 and its 200 day simple moving average is $36.91. Omnicell has a one year low of $22.66 and a one year high of $55.00. The firm has a market cap of $2.10 billion, a PE ratio of 108.58, a price-to-earnings-growth ratio of 4.90 and a beta of 0.78. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.